Similarly, treatment with the 2.5-fold lower simvastatin dose (~20 mg/kg/day) showed a trend for improved EDL force production, but to a more modest extent (~13% increase at 120 Hz; not significant; Supplemental Figure 13A ).
← all excerpts
Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation.
1
—
—